Skip to main content

Table 1 Selected studies

From: Drug costs in the management of metastatic castration-resistant prostate cancer in Canada

Primary medication AA AAwd Abiraterone before docetaxel Abiraterone after docetaxel Docetaxel Cabazitaxel
Source [17] [18] [20] [34] [26] [36]
Median duration of PSA response (months) 12 (3–18)     7.7 (95% CI: 7.1-8.6)  
Median time to PSA progression (months)   5.9 (95% CI: 5.3-10.1) 11.1 10.2   6.4 (IQR: 2.2-10.1)
Mean time to PSA progression (months)       
Progression free-survival (months)    16.5 5.6   2.8 (95% CI: 2.4-3.0)
Rate of mortality 50% 50% at 16.7 months   42% 50% at 18.9 months 62%
at the end of the study &   at the time of preplanned interim analysis & at the time of cut-off
  90% at 60 months    82.8% at 3 years  
Median survival time (months)   16.7 (95% CI: 14.3 - 21.5)   14.8 (95% CI: 14.1-15.4) 18.9 (95% CI: 17–21.2) 15.1 (95% CI: 14.1-16.3)
Median length of follow-up (months) 24 (range: 3–54)   22.2 12.8 20.8 12.8 (IQR:, 7.8-16.9)
Median cycles of treatment     8 (range: 1–21) 9.5* (range: 1–11) 6* (IQR: 3–10)
Median cycle of treatment (monthly equivalent)      7.13 (range: 1–8.3) 5 (IQR: 2.3-7.5)
  1. *3-weekly cycles.
  2. Abbreviations: AA Anti-androgen, AAwd Anti-androgen withdrawal, PSA Prostate-specific antigen, 95% CI 95% confidence interval, IQR Interquartile range.
\